Therefore, we measured RIP1, RIP3, and MLKL concentrations in plasma from HCs, patients with AH, stratified by disease severity based on the model for end-stage liver disease (MELD) score (mild AH [MELD < 11], moderate AH [11 ≤ MELD < 20], severe AH [20 ≤ MELD < 26], very severe AH [MELD ≥ 26]) and patients with NASH. Here, MLKL is linked to metabolic dysfunction-associated steatohepatitis.